http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Design and Analysis of Sub-10 nm Junctionless Fin-Shaped Field-Effect Transistors
Sung Yoon Kim,Jae Hwa Seo,Young Jun Yoon,Gwan Min Yoo,Young Jae Kim,Hye Rim Eun,Hye Su Kang,Jungjoon Kim,Seongjae Cho,Jung-Hee Lee,In Man Kang 대한전자공학회 2014 Journal of semiconductor technology and science Vol.14 No.5
We design and analyze the n-channel junctionless fin-shaped field-effect transistor (JL FinFET) with 10-nm gate length and compare its performances with those of the conventional bulktype fin-shaped FET (conventional bulk FinFET). A three-dimensional (3-D) device simulations were performed to optimize the device design parameters including the width (Wfin) and height (Hfin) of the fin as well as the channel doping concentration (Nch). Based on the design optimization, the two devices were compared in terms of direct-current (DC) and radio-frequency (RF) characteristics. The results reveal that the JL FinFET has better subthreshold swing, and more effectively suppresses short-channel effects (SCEs) than the conventional bulk FinFET.
Comparison of Clinical Stage and Pathologic Stage in Patients with Nonsmall Cell Lung Cancer
( Hye Ran Gwon ),( Sang Hoon Lee ),( Seong Yong Park ),( Seung Hyun Yong ),( A La Woo ),( Song Yee Kim ),( Eun Yeong Kim ),( Ji Ye Jung ),( Young Ae Kang ),( Moo Suk Park ),( Young Sam Kim ) 대한결핵 및 호흡기학회 2021 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.129 No.-
Background Clinical staging of non-small cell lung cancer (NSCLC) is based on radiologic and bronchoscopic finding and mediastinoscopy in the past. Currently, several new techniques including positron emission tomography (PET), endobronchial untrasoundtrnasbronchial needle aspiration (EBUS-TBNA) are available. There is no comparative analysis of clinical stage and pathologic stage after new techniques has been introduced for clinical staging work up. Methods We did a retrospective analysis of 820 patients with NSCLC those who have done curative surgery in Severance hospital from January 2019 to December 2020. The eighth edition of the American Joint Commission of Cancer (AJCC) TNM staging system for NSCLC was used in this study. Results Among 820 patients, most common clinical stage was stage I (671, 81.8%) and most common cancer was adenocarcinoma (680, 83%). For clinical staging work up, EBUS was performed in 265 (32.3%) and PET-CT was performed in 820 (100%) patients. There were 563 (68.7%) patients whose clinical TNM stage and pathologic TNM stage are concurred. When comparing T stage, 637 (77.7%) patients showed matched clinical and pathologic staging. Clinical N stage and pathologic N stage are same in 701 (85.5%) patients. Conclusions The agreement between the clinical stage and the pathologic stage is improved after new diagnostic Methods such as PET, EBUS-TBNA has been introduced for a clinical staging work up.
The Role of Serum Pepsinogen and Gastrin Test for the Detection of Gastric Cancer in Korea
Kang, Jung Mook,Kim, Nayoung,Yoo, Ji Youn,Park, Young Soo,Lee, Dong Ho,Kim, Hyun Young,Lee, Hye Seung,Choe, Gheeyoung,Kim, Joo Sung,Jung, Hyun Chae,Song, In Sung Blackwell Publishing Ltd 2008 HELICOBACTER -CAMBRIDGE USA- Vol.13 No.2
<P>Abstract</P><P>Background and Aim: </P><P>This study was performed to determine whether serum pepsinogen (PG) and gastrin testing can be used to detect gastric cancer in Korea.</P><P>Methods: </P><P>Serum levels of PG I (sPGI) and sPGII, PG I/II ratios, and gastrin levels were measured in 1006 patients with gastroduodenal diseases including cancer. Follow-up tests were performed 1 year after <I>Helicobacter pylori</I> eradication.</P><P>Results: </P><P>sPGI and sPGII levels increased and PG I/II ratios decreased in line with the severity of activity, chronic inflammation, and the presence of <I>H. pylori</I> (<I>p</I> < .01). In contrast, sPGI levels and PG I/II ratios decreased in proportion with the severity of atrophic gastritis (AG)/intestinal metaplasia (<I>p</I> < .01). Gastrin levels were found to be correlated with chronic inflammation negatively in the antrum but positively in the corpus. <I>H. pylori</I> eradication reduced sPGI, sPGII, and gastrin levels, and increased PG I/II ratios to the levels of <I>H. pylori</I>-negative patients, and was found to be correlated with reductions in activity and chronic inflammation of gastritis. The sensitivity and specificity of a PG I/II ratio of ≤ 3.0 for the detection of dysplasia or cancer were 55.8–62.3% and 61%, respectively. In addition, sPGI and sPGII levels of intestinal-type cancer were significantly lower than those of the diffuse type, respectively (<I>p</I> = .008 and <I>p</I> = .05, respectively). Gastric cancer risk was highest in the <I>H. pylori</I>-positive, low PGI/II ratio (≤ 3.0) group with an odds ratio of 5.52 (confidence interval: 2.83–10.77).</P><P>Conclusion: </P><P>PG I/II ratio (≤ 3.0) was found to be a reliable marker for the detection of dysplasia or gastric cancer, especially of the intestinal type. This detection power of PG I/II ratio (≤ 3.0) significantly increased in the presence of <I>H. pylori</I>, and thus, provides a means of selecting those at high risk of developing gastric cancer in Korea.</P>
Nephrotoxic Potential and Toxicokinetics of Tetrabromobisphenol a in Rat for Risk Assessment
Kang, Mi Jeong,Kim, Ju Hyun,Shin, Sil,Choi, Jae Ho,Lee, Sang Kyu,Kim, Hyung Sik,Kim, Nam Deuk,Kang, Geon Wook,Jeong, Hye Gwang,Kang, Wonku,Chun, Young Jin,Jeong, Tae Cheon Informa UK (TaylorFrancis) 2009 Journal of toxicology and environmental health. Pa Vol.72 No.21
<P>Tetrabromobisphenol A (TBBPA), one of the most widely used global brominated flame retardants, is used to improve fire safety of laminates in electrical and electronic equipment. To investigate the nephrotoxic potential of TBBPA and its toxicokinetic profile in rats, single-dose and daily 14-d repeated-dose toxicity studies at 200, 500, or 1000 mg/kg were performed. Several biochemical parameters were analyzed to evaluate nephrotoxicity of TBBPA. High-dose 1000 mg/kg TBBPA significantly elevated renal thiobarbituric acid-reactive substance (TBARS) levels, and superoxide dismutase (SOD) activity was increased at all 3 doses administered. This was associated with no change in the activity of catalase (CAT). Our results suggest that acute 1-d high-dose administration of TBBPA produced transient renal changes at 5 h. Subsequently, TBBPA in serum, urine, and kidney was determined by liquid chromatography-mass spectroscopy (LC/MS). Toxicokinetic studies indicated that TBBPA shows relatively a short half-life (7-9 h) and was eliminated almost completely in feces by 2 d. Based on the results from the 14-d repeated-dose study, TBBPA did not accumulate in the rat, and was eliminated in feces. The present results suggested that TBBPA may not be toxic to kidney, as the chemical is not bioavailable and is not present in renal tissue.</P>